Contract Liabilities
Vertex Pharmaceuticals Contract Liabilities increased by 23.9% to $182.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.3%, from $220.00M to $182.00M. Over 4 years (FY 2020 to FY 2024), Contract Liabilities shows relatively stable performance with a 1.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong future revenue visibility and customer demand, while a decrease may indicate faster fulfillment or slowing sales.
Detailed definition
This represents the obligation to transfer goods or services to a customer for which the company has already received co...
Peer comparison
Common in companies with long-term service contracts or subscription-based diagnostic models; peers with high recurring revenue often show higher balances.
contract_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $122.60M | $104.10M | $171.70M | $186.10M | $134.80M | $119.50M | $159.60M | $236.40M | $179.10M | $157.10M | $170.30M | $275.80M | $128.30M | $220.00M | $206.80M | $228.40M | $146.90M | $182.00M |
| QoQ Change | — | -15.1% | +64.9% | +8.4% | -27.6% | -11.4% | +33.6% | +48.1% | -24.2% | -12.3% | +8.4% | +61.9% | -53.5% | +71.5% | -6.0% | +10.4% | -35.7% | +23.9% |
| YoY Change | — | — | — | — | +10.0% | +14.8% | -7.0% | +27.0% | +32.9% | +31.5% | +6.7% | +16.7% | -28.4% | +40.0% | +21.4% | -17.2% | +14.5% | -17.3% |
Contract Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's contract liabilities?
- Vertex Pharmaceuticals (VRTX) reported contract liabilities of $182.00M in Q3 2025.
- How has Vertex Pharmaceuticals's contract liabilities changed year-over-year?
- Vertex Pharmaceuticals's contract liabilities decreased by 17.3% year-over-year, from $220.00M to $182.00M.
- What is the long-term trend for Vertex Pharmaceuticals's contract liabilities?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's contract liabilities has grown at a 1.9% compound annual growth rate (CAGR), from $191.50M to $206.80M.
- What does contract liabilities mean?
- Money received from customers for products or services that have not yet been delivered.